Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863319 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPT | |
| SCHEMBL1843998 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPT | |
| SCHEMBL29990165 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPT | |
| SCHEMBL3916768 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPT | |
| SCHEMBL3919961 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPT | |
| SCHEMBL5025547 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CRBNDDB1NPC1MAPK13 | |
| SCHEMBL3053841 | 0.75 | DDB1 (0.65) | ALDH1A1CRBNDDB1NPC1MAPK13 | |
| SCHEMBL9405618 | 0.75 | NPC1 (0.47) | ALDH1A1CRBNDDB1NPC1MAPK13 | |
| SCHEMBL1347194 | 0.75 | DDB1 (0.49) | ALDH1A1CRBNDDB1NPC1MAPK13 | |
| SCHEMBL30899479 | 0.75 | ALDH1A1 (0.54) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | ALDH1A1 1523/4885CRBN 1749/4885DDB1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.